Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
This new mandate builds upon and strengthens Azelis and Roquette’s global strategic partnership which spans multiple regions and industries.
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Subscribe To Our Newsletter & Stay Updated
